Nurtec ODT (rimegepant) is manufactured by Biohaven Pharmaceuticals [1]. Biohaven Pharmaceuticals is headquartered in New Haven, Connecticut [2]. The drug itself is produced through contract manufacturing organizations (CMOs) [1].
Who else makes Nurtec?
Biohaven Pharmaceuticals is the sole company that markets and distributes Nurtec ODT. While they utilize contract manufacturing for production, the commercialization and development rights are held by Biohaven [1].
What is Nurtec used for?
Nurtec ODT is a prescription medication approved for two indications. It is used for the acute treatment of migraine with or without aura in adults [1]. Additionally, it is approved for the preventive treatment of episodic migraine in adults [1].
How does Nurtec work?
Nurtec ODT contains the active ingredient rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule implicated in migraine pathophysiology. By blocking the CGRP receptor, rimegepant helps to reduce the inflammation and vasodilation associated with migraine attacks [1].
When does Nurtec's patent expire?
Information regarding specific patent expiry dates for Nurtec ODT is best found through specialized patent databases. DrugPatentWatch.com provides detailed information on drug patents, including expiry dates and any associated litigation [3]. These dates are crucial for understanding when generic versions of the medication might become available.
What are the side effects of Nurtec?
Common side effects reported with Nurtec ODT include nausea and indigestion [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Can insurance cover Nurtec?
Coverage for Nurtec ODT can vary by insurance plan. Biohaven Pharmaceuticals offers a savings program that may help eligible patients with out-of-pocket costs [1]. It is recommended that patients check with their insurance provider and explore available patient assistance programs.